Nuclear expression of β-catenin in endometrial hyperplasia as marker of premalignancy.
Atypical endometrial hyperplasia
endometrial hyperplasia without atypia
endometrial intraepithelial neoplasia
endometrial precancer
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
14
03
2019
accepted:
23
07
2019
pubmed:
14
8
2019
medline:
28
10
2019
entrez:
13
8
2019
Statut:
ppublish
Résumé
We aimed to assess (1)-whether nuclear β-catenin is a marker of endometrial precancer, and (2)-the diagnostic accuracy of β-catenin immunohistochemistry in the differential diagnosis between benign and premalignant endometrial hyperplasia (EH), defining criteria for its use. Electronic databases were searched for studies evaluating β-catenin immunohistochemistry in normal endometrium (NE), benign and/or premalignant EH, and endometrioid carcinoma (EC). Odds ratio (OR; p < 0.05), sensitivity, specificity, diagnostic OR (DOR), positive and negative likelihood ratios (LR+, LR-) were calculated. Subgroup analyses were based on the classification system used (WHO or EIN) and criteria to define aberrant β-catenin expression (only nuclear or cytoplasmic/nuclear). Twelve studies with 1510 specimens were included. Nuclear β-catenin rate significantly increased from NE to benign EH (OR = 26.01; p = 0.0002, only in WHO subgroup), and from benign EH to premalignant EH (OR = 3.89; p = 0.0002; more markedly in EIN subgroup), but not from premalignant EH to EC (OR = 0.78; p = 0.29). Nuclear β-catenin accuracy was very low in WHO subgroup (sensitivity = 0.40, specificity = 0.76, LR+ = 1.85, LR- = 0.72; DOR = 2.89) and moderate in EIN subgroup (sensitivity = 0.19, specificity = 1.00, LR+ = 14.80, LR- = 0.83; DOR = 18.14). Cytoplasmic/nuclear β-catenin accuracy was absent in WHO subgroup (sensitivity = 0.45, specificity = 0.54, LR+ = 1.01, LR- = 1.01; DOR = 0.99) and low in EIN subgroup (sensitivity = 0.57, specificity = 0.86, LR+ = 3.63, LR- = 0.51; DOR = 8.30). Considering nuclear expression and using EIN system, β-catenin immunohistochemistry might be reliable as rule-in test for diagnosis of endometrial precancer, with perfect specificity and moderate overall accuracy.
Substances chimiques
Biomarkers
0
beta Catenin
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
699-709Informations de copyright
© 2019 APMIS. Published by John Wiley & Sons Ltd.
Références
Behrens J. Control of beta-catenin signaling in tumor development. Ann N Y Acad Sci 2000;910:21-33.
Wang Y, van der Zee M, Fodde R, Blok LJ. Wnt/Β-catenin and sex hormone signaling in endometrial homeostasis and cancer. Oncotarget 2010;1:674-84.
Travaglino A, Raffone A, Saccone G, De Luca C, Mollo A, Mascolo M, et al. Immunohistochemical nuclear expression of β-catenin as a surrogate of CTNNB1 Exon 3 mutation in endometrial cancer. Am J Clin Pathol 2019;151:529-38.
Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018;244:538-49.
Nei H, Saito T, Yamasaki H, Mizumoto H, Ito E, Kudo R. Nuclear localization of beta-catenin in normal and carcinogenic endometrium. Mol Carcinog 1999;25:207-18.
Saegusa M, Hashimura M, Yoshida T, Okayasu I. beta-Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001;84:209-17.
Ashihara K, Saito T, Mizumoto H, Nishimura M, Tanaka R, Kudo R. Mutation of beta-catenin gene in endometrial cancer but not in associated hyperplasia. Med Electron Microsc 2002;35:9-15.
Moreno-Bueno G, Hardisson D, Sarrió D, et al. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 2003;199:471-8.
Saegusa M, Hamano M, Kuwata T, Sánchez C, Cassia R, Prat J, et al. Up-regulation and nuclear localization of beta-catenin in endometrial carcinoma in response to progesterone therapy. Cancer Sci 2003;94:103-11.
Brachtel EF, Sánchez-Estevez C, Moreno-Bueno G, Prat J, Palacios J, Oliva E. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am J Surg Pathol 2005;29:1322-9.
Norimatsu Y, Moriya T, Kobayashi TK, Sakurai T, Shimizu K, Tsukayama C, et al. Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women. Ann Diagn Pathol 2007;11:103-8.
Liao X, Siu MK, Au CW, Chan QK, Chan HY, Wong ES, et al. Aberrant activation of hedgehog pathway contributes to endometrial carcinogenesis through beta-catenin. Mod Pathol 2009;22:839-47.
Xiong Y, Xiong YY, Zhou YF. Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma. Eur J Gynaecol Oncol 2010;31:160-4.
Li XC, Song WJ. Endometrial Intraepithelial Neoplasia (EIN) in endometrial biopsy specimens categorized by the 1994 World Health Organization classification for endometrial hyperplasia. Asian Pac J Cancer Prev 2013;14:5935-9.
Senol S, Sayar I, Ceyran AB, Ibiloglu I, Akalin I, Firat U, et al. Stromal clues in endometrial carcinoma: loss of expression of β-catenin, epithelial-mesenchymal transition regulators, and estrogen-progesterone receptor. Int J GynecolPathol 2016;35:238-48.
Strickland AL, Rivera G, Lucas E, John G, Cuevas I, Castrillon DH. PI3K pathway effectors pAKT and FOXO1 as novel markers of endometrioid intraepithelial neoplasia. Int J Gynecol Pathol 2018. https://doi.org/10.1097/pgp.0000000000000549.
Sanderson PA, Critchley HOD, Williams ARW, Arends MJ, Saunders PTK. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update 2017;23:232-54.
Kurman R, Carcangiu M, Herrington C, Young R. World Health Organisation Classification of Tumors of Female Reproductive Organs, 4th ed. Lyon, France: International Agency for Research on Cancer (IARC) Press, 2014.
Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group Gynecol Oncol 2000;76:287-90.
Travaglino A, Raffone A, Saccone G, Mollo A, De Placido G, Insabato L, et al. Endometrial hyperplasia and risk of coexistent cancer: WHO vs EIN criteria. Histopathology 2019;74:676-87.
Baak JP, Mutter GL. EIN and WHO94. J Clin Pathol 2005;58:1-6.
Raffone A, Travaglino A, Saccone G, Insabato L, Mollo A, De Placido G, et al. Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet 2019;299:1233-42.
McCluggage WG. My approach to the interpretation of endometrial biopsies and curettings. J Clin Pathol 2006;59:801-12.
Ordi J, Bergeron C, Hardisson D, McCluggage WG, Hollema H, Felix A, et al. Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification. Histopathology 2014;64:284-92.
Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, et al. Loss of Bcl-2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment. A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018;97:1415-26.
Raffone A, Travaglino A, Saccone G, Mascolo M, Insabato L, Mollo A, et al. PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia. A systematic review and meta-analysis of diagnostic accuracy. Acta Obstet Gynecol Scand 2019;98:287-99.
Raffone A, Travaglino A, Saccone G, Campanino MR, Mollo A, De Placido G, et al. Loss of PTEN expression as diagnostic marker of endometrial precancer: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2019;98:275-86.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.
Sotiriadis A, Papatheodorou SI, Martins WP. Synthesizing evidence from diagnostic accuracy tests: the SEDATE guideline. Ultrasound Obstet Gynecol 2016;47:386-95.
Robbe EJ, van Kuijk SM, de Boed EM, Smits LJ, van der Wurff AA, Kruitwagen RF, et al. Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: immunohistochemical analysis of endometrial samples. Int J Gynecol Cancer 2012;22:1264-72.
Steinbakk A, Gudlaugsson E, Aasprong OG, Skaland I, Malpica A, Feng W, et al. Molecular biomarkers in endometrial hyperplasias predict cancer progression. Am J Obstet Gynecol 2011;204:357.e1-12.
Wang Y, Hanifi-Moghaddam P, Hanekamp EE, Kloosterboer HJ, Franken P, Veldscholte J, et al. Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 2009;15:5784-93.
Villacorte M, Suzuki K, Hirasawa A, Ohkawa Y, Suyama M, Maruyama T, et al. β-Catenin signaling regulates Foxa2 expression during endometrial hyperplasia formation. Oncogene 2013;32:3477-82.
Yoshida T, Hashimura M, Mastumoto T, Tazo Y, Inoue H, Kuwata T, et al. Transcriptional upregulation of HIF-1α by NF-κB/p65 and its associations with β-catenin/p300 complexes in endometrial carcinoma cells. Lab Invest 2013;93:1184-93.
Visser NCM, van der Wurff AAM, Pijnenborg JMA, Massuger LFAG, Bulten J, Nagtegaal ID. Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer. Virchows Arch 2018;472:407-13.
Takahashi H, Yoshida T, Matsumoto T, Kameda Y, Takano Y, Tazo Y, et al. Frequent β-catenin gene mutations in atypical polypoid adenomyoma of the uterus. Hum Pathol 2014;45:33-40.
Travaglino A, Raffone A, Saccone G, Mascolo M, Pignatiello S, Mollo A, et al. PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? APMIS 2019;127:161-9.
Raffone A, Travaglino A, Saccone G, Viggiani M, Giampaolino P, Insabato L, et al. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 2019;299:1511-24.
Lacey JV Jr, Mutter GL, Nucci MR, Ronnett BM, Ioffe OB, Rush BB, et al. Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer 2008;113:2073-81.
Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A, et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005;103:2304-12.
Travaglino A, Raffone A, Saccone G, Mollo A, De Placido G, Mascolo M, et al. Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia. APMIS 2019;127:427-34.
Management of Endometrial Hyperplasia Green-top Guideline No. 67 RCOG/BSGE Joint Guideline | February 2016
Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 2016;22:4215-24.
Giampaolino P, Di Spiezio Sardo A, Mollo A, Raffone A, Travaglino A, Boccellino A, et al. Hysteroscopic endometrial focal resection followed by levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial cancer: a retrospective study. J Minim Invasive Gynecol 2018;26:648-56.
Raffone A, Travaglino A, Saccone G, Alviggi C, Mascolo M, De Placido G, et al. Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review. Acta Obstet Gynecol Scand 2019;98:842-55.
Raffone A, Travaglino A, Saccone G, Mollo A, De Placido G, Insabato L, et al. Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis Acta Obstet Gynecol Scand 2019;98:976-87.
Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, et al. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand 2019;98:976-87.
Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, et al. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2018;231:104-10.